Bae S, Kim SY, Jung JH, Yoon Y, Cha HJ, Lee H, Kim K, Kim J, An IS, Kim J, et al (2012) Akt is negatively regulated by the MULAN E3 ligase. Cell Res 22: 873–885 Braschi E, Goyon V, Zunino R, Mohanty A ...
The NEURL E3 ubiquitin ligases selectively activate the Notch ligands DLL1 and JAG1, but not DLL4 and JAG2. This differential ...
The poster, titled Translational Insights from a First-in-Human Study of an Oral CBL-B Inhibitor in Advanced Solid Tumors, expands upon data presented at the recent European Society for Medical ...
A new study has identified TRIM56, an E3 ubiquitin ligase, as a key activator of the proto-oncogene Src in hepatocellular carcinoma.
The first-of-its-kind study shows that adding a small molecule that blocks the problematic protein to existing cancer ...
Melanoma, the deadliest form of skin cancer, can't always be removed with a scalpel.Patients with advanced stages of melanoma ...
Traditional drug research has focused on creating inhibitors that occupy the active areas of disease-related proteins, preventing them from functioning properly. But this strategy leaves a ...
Haisco Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR (HER1; ...
Beijing Innocare Pharma Tech Co. Ltd. has synthesized E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback